The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals medrxivpreprint UniofNottingham unisouthampton imperialcollege KingsCollegeLon spikeprotein antibodies COVID19
By Pooja Toshniwal PahariaFeb 17 2023Reviewed by Danielle Ellis, B.Sc. *Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
Evaluation of humoral responses to vaccination among immunosuppressed individuals could improve risk stratification and prioritization and facilitate the provision of the highest standard of care to such patients. Rapid point-of-care tests, with results correlating with COVID-19 severity outcome risks, are required to enhance COVID-19 management. Additionally, anti-SARS-CoV-2 antibody testing could quickly identify persons most likely to benefit from COVID-19 interventions.
Participants received at-home LFIA tests for measuring anti-S immunoglobulin G antibody titers and web-based questionnaires to obtain data on sociodemographic variables, COVID-19 vaccination status, prior COVID-19 history, and clinical diagnosis and management of the immunosuppressive condition. The second questionnaire was distributed to obtain data on the shield history, psychological discomfort, LFIA test experience, and results.
Anti-S IgG could not be detected among 23%, 14%, and 21% of SOT recipients, RAIRD patients, and LM patients, respectively. Among all individuals, positive anti-S IgG titers were detected among younger individuals, with an increasingly high number of vaccinations and prior COVID-19 history.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomesResearchers evaluated the effectiveness of nirmatrelvir–ritonavir in preventing coronavirus disease 2019 (COVID-19) severity outcomes during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant predominance.
Lire la suite »
Jamaican fruit bat's response to SARS-CoV-2 adapted to humanIn a recent study posted to the bioRxiv* server, researchers examined the vulnerability of Jamaican fruit bats (Artibeus jamaicensis) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Lire la suite »
Largest ever Yorkshire dinosaur print 'left by lazing giant,' researchers sayResearchers publish findings on an 'amazing' dinosaur print found on Yorkshire's coast.
Lire la suite »
Largest ever Yorkshire dinosaur print 'left by lazing giant,' researchers sayResearchers publish findings on an 'amazing' dinosaur print found on Yorkshire's coast.
Lire la suite »
Death of a zoo hippopotamus underscores the species’ susceptibility to SARS-CoV-2Death of a zoo hippopotamus underscores the species’ susceptibility to SARS-CoV-2 CDCgov EIDjournal covid coronavrius COVID19 SARSCoV2
Lire la suite »
Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antiviralsResearchers performed a retrospective population-wide cohort study using anonymized data in Hong Kong, China, between February 26 and July 3, 2022.
Lire la suite »